Multiple Myeloma Drugs 2017 Global Market Expected to Grow at CAGR 9.19% and Forecast to 2021
WiseGuyReports.Com Publish a New Market Research Report On – “Multiple Myeloma Drugs 2017 Global Market Expected to Grow at CAGR 9.19% and Forecast to 2021”.
Pune, India – January 2, 2017 /MarketersMedia/ —
The analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.
Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.
Download Sample Report @ https://www.wiseguyreports.com/sample-request/855046-global-multiple-myeloma-drugs-market-2017-2021
For more information or any query mail at sales@wiseguyreports.com
Covered in this report
The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
The report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Amgen
• Celgene
• Johnson & Johnson
• Novartis
• Takeda Pharmaceuticals
Other prominent vendors
• AB Science
• AbbVie
• Acceleron Pharma
• Acetylon Pharmaceuticals
• Adaptimmune Therapeutics
• Alexion Pharmaceuticals
• AmpliMed Corporation
• Array BioPharma
• Benovus Bio
• BioInvent
• Biokine Therapeutics
• Biotest
• bluebird bio
• Bristol-Meyer Squibb
• Calithera Biosciences
• CASI Pharmaceuticals
• Celldex Therapeutics
• Cellectar Biosciences
• Chroma Therapeutics
• Cleave Biosciences
• Curis
• Dicerna Pharmaceuticals
• Eureka Therapeutics
• F. Hoffmann-La Roche
• Geron Corporation
• GlycoMimetics
• GlaxoSmithKline
• ImmunoGen
• Immunomedics
• Innate Pharma
• JW Pharmaceutical
• Karyopharm Therapeutics
• Kyowa Hakko Kirin
• Merck
• Midatech Pharma
• Mirna Therapeutics
• Molecular Partners
• MorphoSys
• NOXXON Pharma
• Oncoceutics
• Oncolytics Biotech
• OncoPep
• Oncopeptides
• Ono Pharmaceutical
• Otsuka Pharmaceuticals
• Patrys
• PharmaMar
• Polyphor
• Prothena Therapeutics
• Sanofi
• Sevion Therapeutics
• Specialised Therapeutics
• Spectrum Pharmaceutical
• SymBio Pharmaceuticals
• TaiGen Biotechnology
• Tragara Pharmaceuticals
• Vaxil Therapeutics
• Vivolux
Market driver
• Growing demand for biologic therapies
• For a full, detailed list, view our report
Market challenge
• Growing popularity of complementary and alternative medicines (CAM)
• For a full, detailed list, view our report
Complete Report Details @ https://www.wiseguyreports.com/reports/855046-global-multiple-myeloma-drugs-market-2017-2021
Market trend
• Emergence of nanomedicine platform
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Table Of Contents – Major Key Points
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
PART 06: Pipeline analysis
PART 07: Market landscape
• Global multiple myeloma drugs market
• Five forces analysis
PART 08: Market segmentation by therapy
• Targeted therapy
• Biologic therapy
• Chemotherapy
• Others
PART 09: Geographical segmentation
• Multiple myeloma drugs market in Americas
• Multiple myeloma drugs market in EMEA
• Multiple myeloma drugs market in APAC
PART 10: Market drivers
• Growing demand for biologic therapies
• Paradigm shift toward the adoption of novel proteasome inhibitors
• Presence of large patient pool
PART 11: Impact of drivers
PART 12: Market challenges
• Growing popularity of complementary and alternative medicines (CAM)
• High costs affecting the adoption rates of multiple myeloma drugs
• Adverse effects of drugs
……..CONTINUED
For more information or any query mail at sales@wiseguyreports.com
Check Discount On This Report @ https://www.wiseguyreports.com/check-discount/855046-global-multiple-myeloma-drugs-market-2017-2021
ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.
For more information, please visit https://www.wiseguyreports.com
Contact Info:
Name: Norah Trent
Email: sales@wiseguyreports.com
Organization: WiseGuy Research Consultants Pvt Ltd.
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune – 411028
Phone: +1-646-845-9349
Release ID: 158355